靶向LMO2诱导的自分泌FLT3信号以克服早期T细胞前体急性淋巴细胞白血病的化疗耐药
该研究在Lmo2转基因小鼠、患者来源异种移植和原发ETP-ALL单细胞RNA测序中,发现高表达FLT3的白血病干细胞亚群具有长期自我更新能力且几乎完全耐药。LMO2复合物直接靶向FLT3及其配体,形成自分泌信号环;FLT3抑制剂gilteritinib可损害ETP-ALL体内生长并提高化疗敏感性,还可增强venetoclax应答,为FLT3抑制剂临床试验提供依据。
要点
- ETP-ALL中存在高表达FLT3的白血病干细胞亚群,具长期自我更新能力且几乎完全耐药。
- LMO2复合物直接靶向FLT3及其配体,形成可被gilteritinib靶向的自分泌信号环。
- gilteritinib增强venetoclax应答,可能实现ETP-ALL的「无化疗」治疗。
核心结论
- LMO2驱动的ETP-ALL通过自分泌FLT3信号环介导化疗耐药,靶向该信号可为FLT3抑制剂临床试验提供依据。
研究设计与样本
- 研究分析了Lmo2转基因小鼠、患者来源异种移植和原发ETP-ALL的单细胞RNA测序数据,并结合染色质免疫沉淀和转座酶可及染色质测序。
主要发现
- 高表达FLT3的白血病干细胞亚群虽处于高度增殖状态,但具有长期自我更新能力且几乎完全耐药。
- 染色质免疫沉淀和转座酶可及染色质测序显示FLT3及其配体可能是LMO2干细胞复合物的直接靶点。
- Lmo2转基因胸腺细胞条件培养基显示自分泌FLT3依赖信号环,可被FLT3抑制剂gilteritinib靶向。
- gilteritinib损害ETP-ALL体内生长并提高化疗敏感性。
- gilteritinib增强对BCL2抑制剂venetoclax的应答,可能实现ETP-ALL的「无化疗」治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) is an immature subtype of T-cell acute lymphoblastic leukemia (T-ALL) commonly show deregulation of the LMO2-LYL1 stem cell transcription factors, activating mutations of cytokine receptor signaling, and poor early response to intensive chemotherapy. Previously, studies of the Lmo2 transgenic mouse model of ETP-ALL identified a population of stem-like T-cell progenitors with long-term self-renewal capacity and intrinsic chemotherapy resistance linked to cellular quiescence. Here, analyses of Lmo2 transgenic mice, patient-derived xenografts, and single-cell RNA-sequencing data from primary ETP-ALL identified a rare subpopulation of leukemic stem cells expressing high levels of the cytokine receptor FLT3. Despite a highly proliferative state, these FLT3-overexpressing cells had long-term self-renewal capacity and almost complete resistance to chemotherapy. Chromatin immunoprecipitation and assay for transposase-accessible chromatin sequencing demonstrated FLT3 and its ligand may be direct targets of the LMO2 stem-cell complex. Media conditioned by Lmo2 transgenic thymocytes revealed an autocrine FLT3-dependent signaling loop that could be targeted by the FLT3 inhibitor gilteritinib. Consequently, gilteritinib impaired in vivo growth of ETP-ALL and improved the sensitivity to chemotherapy. Furthermore, gilteritinib enhanced response to the BCL2 inhibitor venetoclax, which may enable "chemo-free" treatment of ETP-ALL. Together, these data provide a cellular and molecular explanation for enhanced cytokine signaling in LMO2-driven ETP-ALL beyond activating mutations and a rationale for clinical trials of FLT3 inhibitors in ETP-ALL.
引用
- Tremblay CS, Saw J, Yan F, et al. Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia. Leukemia. 2025. PMID: 39849166. doi:10.1038/s41375-024-02491-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。